Acute HIV: Symptoms, Diagnosis, and Treatment

Acute HIV infection is the earliest stage of HIV, spanning roughly the first two to four weeks after the virus enters the body, and it is one of the most consequential windows in the entire course of the disease. During this period the virus replicates explosively, the immune system takes massive damage that may never fully recover, and the risk of passing HIV to someone else is far higher than at any other time. Yet the symptoms, when they appear at all, mimic a bad flu or mononucleosis so closely that the majority of acute infections go unrecognized by patients and clinicians alike.

What Acute HIV Symptoms Look Like

The collection of symptoms that can accompany early HIV infection is sometimes called acute retroviral syndrome. In studies that track people from the moment of infection rather than waiting for them to show up at a clinic, the picture is surprisingly inconsistent. One community-based screening study found that about half of people diagnosed with acute HIV reported symptoms at the time of testing, and another quarter recalled symptoms in the two weeks before testing, meaning roughly one in five had no symptoms at all during the acute window.¹ A separate cohort of over 200 people with acute or early HIV found that about 39 percent had no signs or symptoms whatsoever, while 61 percent had at least one and roughly a third had three or more.²

When symptoms do appear, they tend to cluster around fever, sore throat, fatigue, swollen lymph nodes, headache, muscle aches, and sometimes a faint rash. The onset usually comes one to three weeks after exposure, and the illness typically lasts a week or two before resolving on its own, regardless of whether treatment is started. Because these symptoms overlap almost perfectly with mononucleosis and influenza, acute HIV is frequently misdiagnosed. Clinicians are specifically advised to consider acute HIV whenever a patient presents with fever, sore throat, and swollen lymph nodes and tests negative for mono.³

An interesting wrinkle is that symptom severity appears to differ depending on which subtype of HIV a person contracts. A study comparing subtypes across Africa found that people infected with subtype A reported symptoms about 84 percent of the time, while those with subtypes C or D reported symptoms around 60 percent of the time. The median number of symptoms per person was five for subtype A versus just one or two for subtypes C and D.⁴ This means that in regions where subtype C dominates, a larger fraction of acute infections may slip by without any noticeable illness to prompt testing.

What Is Happening Inside the Body

The first few days after HIV enters the body are sometimes called the eclipse phase, a period when the virus is replicating locally in mucosal tissue and nearby lymph nodes but has not yet reached detectable levels in the blood. Research combining molecular dating and viral load measurements estimated this eclipse phase lasts about a week, with peak viral load arriving roughly 20 days after infection.⁵ During the explosive growth that follows, viral levels in the blood can double every 10 hours on average, reaching a peak around three weeks after exposure.⁶

This burst of replication causes damage that is largely invisible to the person experiencing it. More than half of the body’s gut-associated immune cells are destroyed during the first weeks of infection, and this destruction is driven by a combination of direct viral killing, the immune system’s own overreaction, and the death of bystander cells caught in the crossfire.⁷ Even with effective treatment, recovery of these gut immune cells is slow and often incomplete.⁸

The acute phase also triggers a broad inflammatory storm. In untreated acute infection, researchers have documented spikes in at least 12 out of 33 measured immune signaling molecules. Notably, when antiretroviral therapy was started in the very earliest stage of infection, before detectable antibodies formed, this cytokine storm was largely prevented.⁹

The Reservoir Problem

One of the most consequential things that happens during acute infection is the seeding of latent viral reservoirs. These are immune cells that harbor dormant copies of HIV’s genetic material and can reactivate years or even decades later. Research has shown that these reservoirs begin forming during the eclipse phase itself, before the virus is even detectable in the blood.¹⁰ Animal studies have demonstrated that starting treatment as early as three days after infection cannot prevent viral rebound once treatment is paused, underscoring how rapidly the reservoir takes root.

The composition of the reservoir is complex. A genomic analysis found that about 71 percent of the viruses recovered from the long-term reservoir were most closely related to viruses circulating in the blood just before treatment began, suggesting that the act of starting antiretroviral therapy itself may paradoxically help stabilize a large fraction of the reservoir.¹¹ A separate analysis found that roughly 60 percent of reservoir viruses matched strains from the last year before treatment started, with a decay half-life of about nine months going backward from the treatment start date. But the analysis also found an unexpectedly high proportion of reservoir viruses matching strains from the first six months of infection, suggesting that “massive seeding” occurs in those earliest weeks.¹²

This is the central reason acute HIV matters so much for cure research. The reservoir is the main barrier to eliminating HIV from the body, and it is seeded before most people even know they are infected.

How Acute HIV Is Diagnosed

Standard HIV testing evolved through several generations, each closing the gap between the moment of infection and the moment a test can detect it. The earliest antibody-only tests could miss HIV for months. Fourth-generation tests, which look for both antibodies and a viral protein called p24 antigen, shortened that window considerably, detecting infection an average of five to eight days earlier than older antibody-only tests.¹³

Clinicians and researchers sometimes describe the progression of test results using what are called Fiebig stages. In the earliest stage, only viral RNA can be detected by a specialized nucleic acid test. As p24 antigen appears, then antibodies, then a fully developed antibody response, the infection moves through successive stages. A study of 360 participants referred for possible acute infection found that people spent a median of about 13.5 days in the earliest two stages (when only RNA or p24 is detectable) and another 10 days progressing through the later Fiebig stages.¹⁴

Even fourth-generation tests have a known blind spot. After the initial spike in p24 antigen fades and before antibody levels rise high enough, there can be a “second diagnostic window” where the test turns negative again. One documented case showed this window lasting 18 to 34 days on a fourth-generation lab test.¹⁵ This means a person in this window could test negative despite being infected and highly infectious.

For rapid point-of-care tests, newer fourth-generation versions that detect p24 antigen have improved sensitivity, shrinking the diagnostic window from roughly three months down to about one month. But performance in the earliest weeks remains limited: no rapid test in one evaluation was reactive during the first two weeks of infection, and between two and three weeks, the best-performing rapid test detected only about 78 percent of infections.¹⁶ When clinical suspicion for acute HIV is high, a nucleic acid test that directly detects viral RNA remains the most reliable way to catch the infection early.

Testing Accuracy Varies by Region

A complication that rarely makes it into public health messaging is that the performance of rapid diagnostic tests can vary depending on which HIV subtype is circulating in a given area. Most test development and validation has historically focused on subtype B, which predominates in North America and Western Europe. In sub-Saharan Africa, where subtypes A, C, and D are more common, fourth-generation rapid tests have shown notably poorer sensitivity in field studies.¹⁷ A study in Eswatini, where subtype C is dominant, found low sensitivity for the leading fourth-generation rapid test, raising questions about relying on these tools to catch acute infections in the regions where HIV burden is highest.¹⁸ This disparity is a genuine gap in the global response to HIV, and it means that rapid test results in non-B subtype settings should be interpreted cautiously when acute infection is suspected.

Why Starting Treatment During Acute Infection Matters

Current guidelines in most countries recommend starting antiretroviral therapy as soon as possible after diagnosis, and for acute infection the urgency is even greater. Research consistently shows that starting treatment during acute infection leads to lower levels of immune activation, sometimes bringing inflammatory markers close to what you would see in someone without HIV.¹⁹ Starting treatment before the body has developed an antibody response appears to particularly restrict the viral reservoir, and may shift the reservoir’s composition toward a profile that resembles natural viral control.²⁰

Early treatment does not eliminate chronic inflammation entirely, though. One study found that while several inflammatory markers normalized with early treatment, others, including markers of gut barrier damage and general immune activation, remained elevated compared to people without HIV.²¹ This is consistent with the gut immune damage described earlier: once that tissue is destroyed in the first days of infection, recovery is incomplete even with optimal treatment.

Programs that initiate treatment on the same day as diagnosis have shown strong results. In one U.S. public health clinic, patients who began antiretroviral therapy within 24 hours reached undetectable viral levels in a median of about 1.8 months, compared to 4.3 months for patients who started treatment under the usual referral process.²² A study in Taiwan found equivalent outcomes at 12 months whether treatment was started the same day or within a few days, with about 88 percent of patients in both groups reaching full viral suppression.²³ The message from these studies is that there is little downside to starting immediately and meaningful benefit to not waiting.

Transmission Risk During Acute Infection

The astronomical viral load during acute infection translates directly into transmission risk. Blood and genital fluids carry extremely high concentrations of virus during this window. Estimates suggest that a person with acute HIV may be as much as 26 times more infectious than someone with chronic, untreated infection.²⁴ A meta-analysis attempting to quantify the effect found that viral load alone does not fully explain this increased risk; transmission rates during the acute phase were even higher than what the viral load spike would predict, with rate ratios as high as 37 times that of the asymptomatic period when a two-month primary infection window was assumed.²⁵

This finding has significant public health implications. Because most people with acute HIV do not yet know their status, they are not modifying their behavior or taking medication to reduce their viral load. Modeling studies have suggested that a disproportionate share of new HIV transmissions in some communities trace back to people in the acute phase. Catching these infections early through broader testing strategies, including nucleic acid testing in high-risk populations, could interrupt chains of transmission that standard antibody testing simply misses.

Acute HIV and Pre-Exposure Prophylaxis

Pre-exposure prophylaxis, commonly known as PrEP, is taken by people who are HIV-negative to prevent infection. But what happens if someone starts PrEP without realizing they are already in the early stages of acute HIV? This scenario creates a risk of drug resistance. Taking PrEP medications when HIV is already replicating in the body means the virus is exposed to antiretroviral drugs at levels that may suppress it partially but not completely, creating selective pressure for resistant strains. Evidence suggests that drug resistance emerging from PrEP use is uncommon overall, but the cases that do occur are most likely to involve people who began PrEP during undiagnosed acute infection.²⁶

A published case report illustrated this concern in detail. A person initiated PrEP and five months later tested positive on a pooled nucleic acid test while their antibody test remained negative. Over the following months, the infection showed an unusual course: very low viral load, an indeterminate Western blot result, and a transient resistance mutation. Full antibody confirmation and a rise in viral load did not occur until months later.²⁷ Cases like this are one reason guidelines recommend HIV testing at or near the time PrEP is started, ideally including a test sensitive enough to catch very recent infections.

When Symptoms Should Trigger a Clinical Workup

Because acute HIV so closely resembles other common illnesses, it helps to know which situations should raise suspicion. Any flu-like illness or mononucleosis-like presentation in someone with a recent potential HIV exposure warrants further investigation. “Recent” in this context means the prior two to six weeks, because that is the window in which acute symptoms are most likely to develop. Risk factors that should increase suspicion include condomless sex with a new or HIV-positive partner, sharing injection equipment, or occupational needlestick exposure.

A mono test that comes back negative is one of the strongest clinical hints that acute HIV should be considered, because the symptom overlap between mono and acute HIV is nearly complete.³ If a standard fourth-generation HIV test is negative but suspicion remains, the next step is a nucleic acid test that detects viral RNA directly. Waiting for symptoms to resolve and retesting later may confirm the diagnosis, but it also means losing the window when early treatment is most beneficial and when the person is most likely to transmit the virus to others.

Among people who did have symptoms in one cohort, those diagnosed within a month of the estimated date of detectable infection were more likely to report fever, sore throat, and general malaise. Having noticeable acute retroviral syndrome was also associated with a lower eventual immune cell count and a longer time to reach viral suppression, suggesting that a more dramatic initial illness may reflect a more aggressive early infection.² The encouraging news from that same research is that starting treatment immediately appeared to blunt these disadvantages, bringing outcomes closer to those of people who had milder or no symptoms.

What “Undetectable” Does and Does Not Mean After Early Treatment

Once someone begins antiretroviral therapy during acute infection and achieves an undetectable viral load, they can expect the same transmission-prevention benefit as anyone else on effective treatment: a person with a durably suppressed viral load does not transmit HIV sexually. But “undetectable” refers to the virus circulating in the blood. The latent reservoir, nestled inside long-lived immune cells, persists indefinitely with current therapies. Even people treated within the first two weeks of infection, who have the smallest documented reservoirs, experience rapid viral rebound if treatment is interrupted.¹⁰

Researchers continue to investigate whether starting treatment at the earliest possible moment, even during the eclipse phase, can reduce the reservoir enough to make future cure strategies more feasible. For now, the practical reality is that treatment must be lifelong. But the benefits of catching acute infection early are real and measurable: smaller reservoirs, less chronic inflammation, better immune preservation, and a dramatically shorter period of high infectiousness. The challenge is that most of the tools available for routine testing are still playing catch-up with a virus that does its worst damage in the first days after arrival.